$24,50
▼ $-0,60
(-2,39%)
Vol. 2.0M
2
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$5.1B
ROE
-84,9%
D/E
0,00
Beta
0,55
52W
$13–$28
Consenso Wall Street
24 analisti · Apr 20269
Acquisto forte
9
Compra
6
Mantieni
0
Vendi
0
Vendita forte
75,0%
Rating Compra
Grafico dei Prezzi
Titoli simili
ERAS
Erasca Inc
$1.1B
CAI
Caris Life Sciences Inc
$7.6B
CELC
Celcuity Inc
$4.6B
TGTX
TG Therapeutics Inc
P/E 10,6
$4.7B
APLS
Apellis Pharmaceuticals Inc
P/E 70,7
$3.2B
APGE
Apogee Therapeutics Inc
$5.2B
DNTH
Dianthus Therapeutics Inc
$1.8B
FOLD
Amicus Therapeutics Inc
$4.4B
VKTX
Viking Therapeutics Inc
$4.0B
ACAD
ACADIA Pharmaceuticals Inc
P/E 17,3
$4.5B
Utili
Tasso di battuta: 75,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-0,73 | $-0,61 | +$0,12 |
| Set 2025 | $-0,73 | $-0,73 | +$0,00 |
| Giu 2025 | $-0,66 | $-0,71 | $-0,05 |
| Mar 2025 | $-0,73 | $-0,64 | +$0,09 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — | — |
| Utile netto | — | -$111.1M | -$106.4M | -$120.6M | -$126.5M | -$110.6M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -84.4% | -80.6% | -84.5% | -84.5% | -84.9% | -84.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 12.32 | 11.16 | 12.32 | 12.32 | 9.07 | 9.07 |
Rapporti chiave
ROA (TTM)
-76,1%
P/B
4,1
EPS (TTM)
$-2,83
CF/Share
$-1,96
52W High
$27,69
52W Low
$12,72
$12,72
Intervallo 52 settimane
$27,69
Salute finanziaria
Flusso di cassa libero
-$92.3M
Liquidità
$994.5M
Aggiornato al Dic 31, 2025
Як IMVT виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка IMVT vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
—
▼
0%
sotto
peer
(12,9)
vs Peer
vs Settore
Sopravvalutato
P/B
4,1
▲
67%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість IMVT vs аналоги Biotechnology
ROE
-84,9%
▼
26%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Sotto media
Net margin
—
▼
0%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Top livello
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-76,1%
▼
63%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя IMVT vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
9,1
▲
104%
sopra
peer
(4,4)
vs Peer
vs Settore
Liquidità forte
Beta
0,6
▼
43%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів IMVT
IMVT
Mediana peer
Industria
IMVT прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
IMVT vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
VAN TUYL CHRISTOPHER
Officer · Mar 18
2877 shs
GLORIA MELANIE
Chief Operating Officer · Feb 25
3238 shs
STOUT JAY S
Chief Technology Officer · Gen 21
1977 shs
STOUT JAY S
Chief Technology Officer · Gen 07
1203 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 23,63%FMR, LLC
8,35%
$408.5M
Deep Track Capital, Lp
5,66%
$277.1M
Vanguard Group Inc
3,82%
$187.0M
Blackrock Inc.
2,98%
$145.6M
Armistice Capital, LLC
2,82%
$138.2M
Aggiornato al Dic 31, 2025